Ximluci® (Xlucane™)
Neovascular (wet) Age-Related Macular Degeneration (AMD) (ranibizumab biosimilar)
BLA ResubmissionActive
Key Facts
Indication
Neovascular (wet) Age-Related Macular Degeneration (AMD) (ranibizumab biosimilar)
Phase
BLA Resubmission
Status
Active
Company
About Xbrane Biopharma
Xbrane Biopharma is a publicly traded Swedish biopharmaceutical company focused on developing and commercializing biosimilars for major diseases like cancer and macular degeneration. Its core competitive advantage is a patented production technology that dramatically increases protein yield, enabling up to an 80% cost reduction compared to standard systems. The company's lead asset is a ranibizumab biosimilar (Ximluci®/Xlucane™) for wet AMD, with a BLA resubmission to the FDA planned, and a second candidate (Xdivane™) in pivotal trials for cancer. Xbrane's strategy targets originator markets worth over SEK 100 billion.
View full company profile